Investigational drug · Phase 3
DMT310
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acne Vulgaris.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "DMT310"
First trial start
2023
Dec 8, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DMT310", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acne Vulgaris
Approved drugs for the same conditions: Acne · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "DMT310" as an intervention, largest first.
- DMT310-009 Topical in the Treatment of Acne VulgarisPivotal-lookingCompleted
Dermata TherapeuticsIndustry
NCT06090721 · 520 participants · Start Dec 8, 2023 · Primary completion Mar 31, 2025
Drug: DMT310; Placebo · For: Acne Vulgaris
Sites: Freemont, California; Austin, Texas
- DMT310-003 Topical in the Treatment of Acne VulgarisPivotal-lookingCompleted
Dermata TherapeuticsIndustry
NCT04106778 · 181 participants · Start Oct 10, 2019 · Primary completion May 4, 2020
Drug: DMT310; Placebo · For: Acne Vulgaris
Sites: Austin, Texas
- DMT310-005 Topical in the Treatment of Acne RosaceaPivotal-lookingStatus unknown
Dermata TherapeuticsIndustry
NCT05108025 · 180 participants · Start Nov 15, 2021 · Primary completion Dec 2022
Drug: Topical Powder; Placebo Topical Powder · For: Acne Rosacea
Sites: Austin, Texas
- DMT310-001 Topical in the Treatment of Acne VulgarisPivotal-lookingCompleted
Dermata TherapeuticsIndustry
NCT03536637 · 121 participants · Start May 22, 2018 · Primary completion Dec 30, 2018
Drug: DMT310; Hydrogen Peroxide and 1 more · For: Acne Vulgaris
Sites: San Diego, California; Saint Joseph, Missouri; Henderson, Nevada · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- DMT310, a novel once-weekly topical treatment for patients with moderate-to-severe acne vulgaris: Results of a phase 2b randomized, double-blind, placebo-controlled trial.
Eichenfield LF, DuBois JC, Gold MH, et al. · J Am Acad Dermatol 2023
Also in development for Acne Vulgaris
- DenifanstatPhase 31 trial
Sagimet Biosciences Inc. · Acne Vulgaris
- HB0043Phase 22 trials
Shanghai Huaota Biopharmaceutical Co., Ltd. · Acne Vulgaris, Hidradenitis Suppurativa
- B244Phase 21 trial
AOBiome LLC · Acne Vulgaris
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.